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sion of other severe HST-related complications. Primary end-
points were response to treatment after 14 and 28 days. Secondary
endpoints were side effects and incidence of infectious complica-
tions. Treatment consisted of Campath 1H 10mg given s.c. on days
1-5. Median age was 33 years old (range:1-59) years, a ﬂudarabine-
based reduce intensive conditioning (RIC) regimen was used and
the hematopoietic cells were obtained from HLA-identical siblings
in 12 cases and one patient received stem cell from umbilical cord
blood. All but one received CSA and MTX for GvHD prophylaxis.
GvHD was classiﬁed as grade II in 5 patients, III in 6 and IV in 2;
predominant organ affected was gut in 6 cases, skin in 7, liver in 4
and combination of gut and skin in 4 patients. In 6 of the 13
patients the clinical manifestations of GVHD were noticed after
the ﬁrst 100 days of HSCT. Complete resolution of GvHD, partial
response and no response were seen respectively in 23%, 62% and
15%. Six over the 13 patients were able to decrease steroid use.
Five patients developed CMV (pp65) reactivation and 3 of them
were successfully treated with valganciclovir. All patients main-
tained complete chimerism during and after alemtuzumab therapy,
and after a median follow-up of 5 months (range, 1- 18months), 8
remain alive, 3 without evidence of GVHD. Five patients died, 3
due to GvHD and the others due to infectious complications. This
preliminary study suggests that alemtuzumab is a well-tolerated
agent and has a beneﬁcial effect in the treatment of refractory
GvHD. It is only a pilot study and more studies are needed, but we
suggest that this modality could be used early in the management
of these patients in order to improve quality of life and reduce the
long-term side effects of corticosteroids.
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We previously showed that antithymocyte globuline (ATG)
given with TBI 200 cGy and ﬂudarabine results in high rate of
donor engraftment. Its inﬂuence on acute and chronic graft versus
host disease (GVHD) and on graft versus tumor effect is less
known. The reported rates of acute, grade II-IV GVHD after
non-myeloablative stem cell transplantation (NST) have ranged
from 20% to 58%. In the setting of NST, advanced recipient
and/or donor ages increase the risk of GVHD. In addition, treat-
ment of GVHD with high doses of corticosteroids is poorly tol-
erated in older adults. For these reasons, strategies to decrease the
incidence and severity of GVHD in NST are needed. Sixty-ﬁve
patients underwent non myeloablative stem cell transplant using
ATG horse derived 15mg/kg/day x 4 days or rabbit derived 1.5
mg/kg/day x 4 doses on days -4 to -1, TBI 200 cGy in a single
fraction given on day -5 and ﬂudarabine 30mg/m2/day x 3 doses on
days -4 to -2. Mycophenolate mofetil (MMF) 15mg/kg twice daily
and cyclosporine (CSA) 6 mg/kg twice daily were started on day -5
for GVHD prophylaxis. Patients characteristics is summarized in
Table 1. Between 30 to 60 days post transplant peak donor chi-
merism 80% was documented in 54 patients (93%) and 50-80%
donor chimerism in 4 pts (7%). At a median follow up of 862 days,
24 patients (37%) developed GVHD. The median age of the
patients with and without GVHD was 56 years respectively. Acute
GVHD (aGVHD) grade II-IV developed in 19 pts (29%). Fatal
GVHD of liver and/or gut occurred in nine pts (14%). Forty one
patients survived more than 100 days. Five patients (12%) had
chronic GVHD (cGVHD), two had extensive and three limited
involvement. Relapsed disease was observed in 22 patients (34%).
Relapsed disease was the main cause of death in patients with AML
9/13 (69%). Six patients with AML had relapsed/refractory disease
at the time of transplant. Relapse rate for patients with NHL was
29% and 33% for those with MM. Sixteen patients (25%) are alive
in CR (10 NHL and 3 MM and 3 MDS/MPD), with a median
follow up of 862 days. Infections occurred in 15 patients (23%) and
were fatal in 13 (20%). Our study conﬁrms the usefulness of ATG
in the prevention of acute and chronic graft-versus-host disease
after NST. Except for some caveats related to donor type, we were
not able to demonstrate a major impact in the rate of grade III and
IV aGVHD owing to the use of ATG. The best transplant out-
comes were seen in patients with lymphoid malignancies.
Table 1: Patients Characteristics
N 65
Age (median/range) 56 (19-71)
Male/Female 41/24
Donor
Age (median/range) 48 (20-71)
Male/Female 33/32
Matched related 42 (65%)
Matched unrelated 18 (28%)
Mismatch related 1 (1.5%)
Mismatch unrelated 4 (6%)
Female donor/Male recipient 20 (31%)
Diagnosis (%)
NHL 21 (32%)
MM 15 (23%)
AML 13 (20%)
MDS 4 (6%)
MPD 4 (6%)
ALL 2 (3%)
CLL 2 (3%)
PNH/SAA 2 (3%)
HD 1 (1.5%)
CML 1 (1.5%)
Stem cell source (%)
G-PBPC 58 (89%)
Marrow 7 (11%)
Prior ASCTx (%) 11 (17%)
Median follow up for patients alive 862 days
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Objective: To assess the activity and toxicity of etanercept in the
salvage treatment of patients with chronic graft versus host disease
(cGVHD) failing steroids or further therapy. Patients/Methods:
Retrospective study of all patients with moderate to severe
cGVHD seen in our GVHD clinic from 11/2004 to 11/2005, who
received etanercept for the treatment of cGVHD. The diagnosis
and staging of cGVHD was based on NIH Consensus criteria. All
patients were either steroid refractory (progressive disease (PD),
stable disease (SD) or partial response (PR) despite prolonged
treatment with steroids) or steroid dependent (ﬂaring after steroid
discontinuation). Results: We identiﬁed a total of 9 patients
treated with etanercept. Organs involved included: skin (n7, 6
with sclerosis), lung (n1), eye (n3) and mouth (n1). Four
patients had involvement of cGVHD in more than 1 organ site. All
patients receive salvage with other agents in addition to steroids
prior to receiving etanercept. Seven received sirolimus, 7 received
extracorporeal photopheresis (ECP), 2 received mycophenolate
mofetil, 1 received inﬂiximab, 2 received hydroxychloroquine, and
1 received thalidomide. At initiation of etanercept, 7 patients were
on steroids, 6 patients continued ECP and 3 patients continued
multi-drug salvage regimens. Patients received etanercept 50 mg
subcutaneously (SC) weekly. Only 1 patient had a reduction in dose
to 50 mg SC every other week when response was noted. Overall
response rate was 56 % (5/9). Three of 6 patients with sclerosis had
a response, one was a complete response and 2 had a PR. The
patient with lung cGVHD had a PR and the patient cGVHD of the
mouth had a PR. Patients received between 4 to 80 doses (4
patients received greater then 20 doses) of etanercept 50 mg SC
weekly. Five of the seven patients on corticosteroids were able to
taper within one month of starting etanercept. The patient with
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